Literature DB >> 18054103

Evaluation of margining algorithms in commercial treatment planning systems.

Alistair M Pooler1, Helen M Mayles, Olivia F Naismith, John P Sage, David P Dearnaley.   

Abstract

INTRODUCTION: During commissioning of the Pinnacle (Philips) treatment planning system (TPS) the margining algorithm was investigated and was found to produce larger PTVs than Plato (Nucletron) for identical GTVs. Subsequent comparison of PTV volumes resulting from the QA outlining exercise for the CHHIP (Conventional or Hypofractionated High Dose IMRT for Prostate Ca.) trial confirmed that there were differences in TPS's margining algorithms. Margining and the clinical impact of the different PTVs in seven different planning and virtual simulation systems (Pinnacle, Plato, Prosoma (MedCom), Eclipse (7.3 and 7.5) (Varian), MasterPlan (Nucletron), Xio (CMS) and Advantage Windows (AW) (GE)) is investigated, and a simple test for 3D margining consistency is proposed.
METHODS: Using each TPS, two different sets of prostate GTVs on 2.5mm and 5mm slices were margined according to the CHHIP protocol to produce PTV3 (prostate+5 mm/0 mm post), PTV2 (PTV3+5 mm) and PTV1 (prostate and seminal vesicles+10 mm). GTVs and PTVs were imported into Pinnacle for volume calculation. DVHs for 5mm slice plans, created using the smallest PTVs, were recalculated on the largest PTV dataset and vice versa. Since adding a margin of 50 mm to a structure should give the same result as adding five margins of 10 mm, this was tested for each TPS (consistency test) using an octahedron as the GTV and CT datasets with 2.5 mm and 5 mm slices.
RESULTS: The CHHIP PTV3 and PTV1 volumes had a standard deviation, across the seven systems, of 5% and PTV2 (margined twice) 9%, on the 5 mm slices. For 2.5 mm slices the standard deviations were 4% and 6%. The ratio of the Pinnacle and the Eclipse 7.3 PTV2 volumes was 1.25. Rectal doses were significantly increased when encompassing Pinnacle PTVs (V(50)=42.8%), compared to Eclipse 7.3 PTVs (V(50)=36.4%). Conversely, fields that adequately treated an Eclipse 7.3 PTV2 were inadequate for a Pinnacle PTV2. AW and Plato PTV volumes were the most consistent (0.3%) and (-0.4%). However, the 1x50mm margin in Pinnacle produced a 15.9% larger volume than 5 x 10 mm margins, while for Eclipse 7.3 the single margined volume was 14.3% smaller. These inconsistencies were reduced to approximately 5% by adjusting the superior/inferior margins.
CONCLUSIONS: Accurate margin algorithms are necessary to ensure that volume expansion does not add extra uncertainty to the radiotherapy planning process. We have found significant differences in the 3D margining algorithms of TPSs, devised a simple test to predict inconsistency and suggested corrective action to minimise the variation.

Entities:  

Mesh:

Year:  2007        PMID: 18054103     DOI: 10.1016/j.radonc.2007.11.006

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  4 in total

Review 1.  Improving radiotherapy quality assurance in clinical trials: assessment of target volume delineation of the pre-accrual benchmark case.

Authors:  S Gwynne; E Spezi; D Sebag-Montefiore; S Mukherjee; E Miles; J Conibear; J Staffurth
Journal:  Br J Radiol       Date:  2013-02-07       Impact factor: 3.039

2.  A simple method of evaluating margin-growing accuracy in image-guided radiation therapy.

Authors:  Ying Wang; Fu Jin; Juan Zhou; Huanli Luo
Journal:  Br J Radiol       Date:  2016-03-23       Impact factor: 3.039

3.  Dependence of volume calculation and margin growth accuracy on treatment planning systems for stereotactic radiosurgery.

Authors:  David J Eaton; Kevin Alty
Journal:  Br J Radiol       Date:  2017-10-12       Impact factor: 3.039

4.  Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity.

Authors:  O F Naismith; C Griffin; I Syndikus; C South; H Mayles; P Mayles; V Khoo; C Scrase; J Graham; S Hassan; E Hall; D P Dearnaley
Journal:  Clin Oncol (R Coll Radiol)       Date:  2019-06-06       Impact factor: 4.126

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.